Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update
Rhea-AI Summary
Opus Genetics (Nasdaq: IRD) reported second quarter 2026 license and collaborations revenue of $0.8 million, down from $2.9 million a year earlier, and a net loss of $8.1 million, or $0.08 basic and $0.14 diluted per share. R&D expenses rose to $11.2 million from $6.0 million, while G&A expenses were $6.0 million versus $5.8 million.
As of June 30, 2026, cash and cash equivalents were $88.8 million, and the company expects existing cash plus potential note funding to support operations into 2029. Opus Genetics completed Cohort 1 enrollment in its OPGx‑BEST1 Phase 1/2 trial with 3‑month topline data targeted for the second week of September 2026 and finalized the registrational Phase 3 OPGx‑LCA5 trial design with enrollment complete and dosing planned for Q4 2026. Additional gene therapy programs targeting RDH12, MERTK and RHO are expected to enter clinical testing between Q4 2026 and the second half of 2027.
Positive
- Cash and cash equivalents $88.8 million at June 30, 2026, versus $45.1 million at December 31, 2025
- Cash runway into 2029 expected when including potential future Oberland note funding
- OPGx-BEST1 Phase 1/2 Cohort 1 enrollment completed; 3‑month topline data expected second week of September 2026
- OPGx-LCA5 registrational Phase 3 design aligned with FDA; enrollment complete, dosing planned Q4 2026
- Multiple new clinical entries planned: RDH12 in Q4 2026, MERTK in Q1 2027, RHO in 2H 2027
- Fair value change in instruments contributed $7.2 million income in Q2 2026 versus $0.9 million in Q2 2025
Negative
- License and collaborations revenue declined to $0.8 million from $2.9 million year over year in Q2
- R&D expenses increased to $11.2 million from $6.0 million in Q2, driven by higher manufacturing and clinical costs
- Net loss Q2 2026 widened to $8.1 million from $7.4 million year over year
- Six‑month 2026 net loss was $73.6 million versus $15.6 million in the prior‑year period
- Stockholders’ equity moved to a deficit of $13.0 million at June 30, 2026, from positive $15.3 million at year‑end 2025
- Long‑term debt and warrant liabilities reached $34.9 million and $62.1 million, respectively, at June 30, 2026
News Explained
The reported share increase creates potential dilution while the June 30 balance sheet also carries long-term debt and negative stockholders’ equity.
Opus Genetics reported second-quarter 2026 results; as of
The same balance sheet reported long-term debt of
Cash and equivalents were
The key balance-sheet items to track in the next filing are the share count, long-term debt, and funding agreement, because they will show how the reported ownership and financing position develops.
Sources and calculations
- Opus Genetics second-quarter 2026 results and corporate update (2026-08-06)
- Opus Genetics first-quarter 2026 fundamentals (2026Q1)
- Cash and equivalents vs quarterly operating cash outflow, in days of cash use $59,959,000 / ($12,727,000 / 90) = [object Object]
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 12 | Q1 2026 earnings | Positive | +1.2% | Pipeline milestones and runway into 2029 accompanied first-quarter financial results. |
| Mar 10 | FY 2025 earnings | Positive | +1.7% | Year-end cash, financing, clinical progress, and regulatory milestones accompanied annual results. |
| Nov 12 | Q3 2025 earnings | Positive | -2.5% | Positive LCA5 data and regulatory progress accompanied third-quarter results. |
| Aug 13 | Q2 2025 earnings | Positive | +7.3% | FDA designation, positive clinical data, and improved revenue accompanied second-quarter results. |
| May 15 | Q1 2025 earnings | Neutral | +0.0% | Clinical progress and financing updates accompanied first-quarter financial results. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings-specific history showed mostly positive or flat 24-hour reactions, with one negative reaction.
Key Terms
phase 3 medical
six-month run-in period medical
priority review vouchers regulatory
aav-based technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
OPGx-BEST1 Cohort 1 Topline Data Expected in Second Week of September 2026
Enrollment Completed in LCA5 Registrational Trial with Dosing Planned for Q4 2026
RDH12, MERTK and RHO Programs Advancing with Upcoming Initiation of Clinical Testing
Cash Runway into 2029 Expected to Support Multiple Clinical Inflection Points and Opportunities for Priority Review Vouchers
RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced financial results for the second quarter ended June 30, 2026, and provided a corporate update.
“With a focus on execution, we are rapidly advancing five gene therapy programs that address significant unmet need in inherited retinal diseases, with OPGx-BEST1 Cohort 1 clinical data targeted for the second week of September and four additional clinical readouts expected in 2027,” said George Magrath, M.D., Chief Executive Officer of Opus Genetics. “Based on recent FDA interactions, we finalized the OPGx-LCA5 registrational trial design. We have completed enrollment and expect to initiate participant dosing in the fourth quarter of this year. Our recent R&D Science Forum highlighted the significant progress we have made in advancing our pipeline. Our strong cash runway into 2029 positions us to initiate new clinical studies, deliver multiple data inflection points, pursue potential product approvals, and unlock opportunities for Priority Review Vouchers.”
Pipeline Updates
OPGx-BEST1
- Enrollment was completed in Cohort 1 of the Phase 1/2 trial (BIRD-1), with 3-month topline data from Cohort 1 expected during the second week of September 2026, assuming all participants complete their assessments as scheduled.
- Baseline demographics were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting with the related poster presentation available on the Publications & Presentations page of the Opus Genetics website. Additionally, a slide presentation and video summary recording titled “OPGx-BEST1 Cohort 1 Baseline Demographics and Key Endpoints for IRDs” are provided on the OPGx-BEST1 Program section of the Opus Genetics website.
OPGx-LCA5
- Alignment was achieved with the U.S. Food and Drug Administration (FDA) on the registrational Phase 3 clinical trial evaluating OPGx-LCA5 in eight participants with a six-month run-in period, allowing each participant to serve as their own control, prior to receiving treatment in both eyes.
- Enrollment in the trial was completed, with dosing of OPGx-LCA5 expected to begin in the fourth quarter of 2026 using clinical drug supply manufactured with the intended commercial processes. Topline data from the study is expected by the end of 2027.
OPGx-RDH12
- The OPGx-RDH12 program is expected to enter the clinic in the fourth quarter of 2026 and is partially funded through a partnership with the RDH12 Alliance.
OPGx-MERTK
- The OPGx-MERTK program is expected to initiate clinical testing at the Cleveland Clinic Abu Dhabi in the first quarter of 2027.
OPGx-RHO
- Preclinical data presented at ARVO 2026 and the Foundation Fighting Blindness Retinal Therapeutics Innovation Summit 2026 provided safety and efficacy data on the use of OPGx-RHO in two large animal models of autosomal-dominant retinitis pigmentosa (adRP).
- The OPGx-RHO program is expected to initiate clinical testing globally in the second half of 2027.
Recent Medical Presentations
Opus Genetics delivered numerous data presentations at prominent medical meetings during the period including at the Association for Research in Vision and Ophthalmology (ARVO), Retina World Congress, and the American Society of Gene & Cell Therapy. In addition, in July 2026, Human Gene Therapy published “Evaluation of the Toxicity and Efficacy of an Adeno‑Associated Viral Vector Expressing BEST1 Delivered by Subretinal Injection in a Canine Model of Human Bestrophinopathy”. All materials can be found on the Publications & Presentations page of the Company website.
Financial Results for the Second Quarter Ended June 30, 2026
Cash Position: As of June 30, 2026, Opus Genetics had cash and cash equivalents of
Revenue: License and collaborations revenue totaled
Research and Development (R&D) Expenses: R&D expenses were
General and Administrative (G&A) Expenses: G&A expenses were
Net Loss: Net loss for the quarter ended June 30, 2026 was
About Opus Genetics
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RDH12, MERTK, RHO, CNGB1 and NMNAT1. The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements related to cash runway and future financing availability, potential future funding under the Oberland facility, potential product approvals, and Priority Review Voucher opportunities, the clinical development, clinical results, preclinical data and future plans for Phentolamine Ophthalmic Solution
Contacts:
Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
ir@opusgtx.com
Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
| Opus Genetics, Inc. Condensed Consolidated Balance Sheets (in thousands, except share amounts and par value) | |||||||
| As of | |||||||
| June 30, 2026 | December 31, 2025 | ||||||
| Assets | (Unaudited) | ||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 88,812 | $ | 45,091 | |||
| Accounts receivable | 1,041 | 1,995 | |||||
| Contract assets and unbilled receivables (Note 12) | 415 | 1,170 | |||||
| Prepaids and other current assets | 2,428 | 1,788 | |||||
| Total current assets | 92,696 | 50,044 | |||||
| Property and equipment, net | 172 | 199 | |||||
| Restricted cash | 100 | — | |||||
| Total assets | $ | 92,968 | $ | 50,243 | |||
| Liabilities, convertible preferred stock and stockholders’ (deficit) equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 1,881 | $ | 3,293 | |||
| Accrued expenses | 5,724 | 4,488 | |||||
| Total current liabilities | 7,605 | 7,781 | |||||
| Long-term debt | 34,932 | — | |||||
| Warrant liabilities | 62,145 | 25,985 | |||||
| Funding agreement, related party | 1,272 | 1,129 | |||||
| Total liabilities | 105,954 | 34,895 | |||||
| Commitments and contingencies (Note 4 and Note 11) | |||||||
| Stockholders’ (deficit) equity: | |||||||
| Preferred stock, par value | — | — | |||||
| Common stock, par value | 8 | 7 | |||||
| Additional paid-in capital | 249,228 | 203,930 | |||||
| Accumulated deficit | (262,222 | ) | (188,589 | ) | |||
| Total stockholders’ (deficit) equity | (12,986 | ) | 15,348 | ||||
| Total liabilities, convertible preferred stock and stockholders’ (deficit) equity | $ | 92,968 | $ | 50,243 | |||
| Opus Genetics, Inc. Condensed Consolidated Statements of Comprehensive Loss (in thousands, except share and per share amounts) (Unaudited) | |||||||||||||||
| For the Three Months Ended June 30, | For the Six Months Ended June 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| License and collaborations revenue | $ | 755 | $ | 2,882 | $ | 2,912 | $ | 7,252 | |||||||
| Operating expenses: | |||||||||||||||
| Research and development | 11,207 | 6,022 | 21,784 | 13,975 | |||||||||||
| General and administrative | 6,028 | 5,766 | 11,972 | 12,112 | |||||||||||
| Total operating expenses | 17,235 | 11,788 | 33,756 | 26,087 | |||||||||||
| Loss from operations | (16,480 | ) | (8,906 | ) | (30,844 | ) | (18,835 | ) | |||||||
| Fair value change in instruments measured at fair value | 7,174 | 917 | (44,190 | ) | 3,722 | ||||||||||
| Financing costs | (531 | ) | 35 | (1,113 | ) | (1,337 | ) | ||||||||
| Other income, net | 1,739 | 534 | 2,514 | 836 | |||||||||||
| Loss before income taxes | (8,098 | ) | (7,420 | ) | (73,633 | ) | (15,614 | ) | |||||||
| Benefit (provision) for income taxes | — | — | — | — | |||||||||||
| Net loss | (8,098 | ) | (7,420 | ) | (73,633 | ) | (15,614 | ) | |||||||
| Other comprehensive loss, net of tax | — | — | — | — | |||||||||||
| Comprehensive loss | $ | (8,098 | ) | $ | (7,420 | ) | $ | (73,633 | ) | $ | (15,614 | ) | |||
| Net loss per share: | |||||||||||||||
| Net loss per share - basic | $ | (0.08 | ) | $ | (0.12 | ) | $ | (0.81 | ) | $ | (0.32 | ) | |||
| Net loss per share - diluted | $ | (0.14 | ) | $ | (0.12 | ) | $ | (0.81 | ) | $ | (0.32 | ) | |||
| Number of shares used in per share calculations: | |||||||||||||||
| Weighted average shares outstanding - basic | 95,483,280 | 63,376,392 | 91,211,050 | 48,712,124 | |||||||||||
| Weighted average shares outstanding - diluted | 111,384,011 | 63,376,392 | 91,211,050 | 48,712,124 | |||||||||||
Source: Opus Genetics, Inc.
